Apr. 16 at 11:05 AM
RBC Capital, on 4/15,🏁
$ASND Outperform-
$205.
$AZN $MBX $NVO BBIO
RBC Capital said in its initiation report, "Stock has outperformed the
$XBI lately, but we see upside from here given that our extensive checks with multiple docs (including a proprietary global survey of 50 endocrinologists) suggests that Yorvipath will be a €3b drug (vs €2b consensus) and
$ASND has a golden opportunity to capitalize on first-mover advantage given
$AZN is unlikely differentiated and
$MBX materially behind.
RBC Capital went on to say:
